GlassScriptPhysician profile
Prem Kg Chandran
NPI 1518969104
$18,836.63
in general payments reported to CMS, 2019-2025
30 companies · $1,535 in 2025
The $1,535 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $1,280 · 2021: $2,293 · 2022: $1,652 · 2023: $437 · 2024: $11K · 2025: $1,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,700 · Food and Beverage: $2,680 · Travel and Lodging: $1,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,700.00 |
| Food and Beverage | $2,680.41 |
| Travel and Lodging | $1,736.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $9,609.54 | 2024 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $5,320.11 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $1,882.43 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $405.33 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $204.39 | 2023-2025 | Tarpeyo |
| Amgen INC. | $173.98 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $159.68 | 2019-2025 | Farxiga |
| Mallinckrodt Enterprises LLC | $143.76 | 2019 | |
| Vifor Pharma, INC. | $139.07 | 2019-2024 | Veltassa |
| Madrigal Pharmaceuticals | $133.29 | 2024 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.71 | 2023-2025 | Jardiance |
| Immucor, INC. | $113.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.72 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.76 | 2020-2024 | Gattex |
| Veloxis Pharmaceuticals, INC. | $37.53 | 2025 | Envarsus |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $32.72 | 2019 | |
| Cormedix INC. | $30.80 | 2024 | Defencath |
| Genentech USA, INC. | $29.78 | 2025 | Gazyva |
| Baxter Healthcare | $25.92 | 2024 | Renal - Pd |
| Fresenius USA Marketing, INC. | $23.57 | 2019 | |
| Daiichi Sankyo INC. | $23.09 | 2019 | |
| Scpharmaceuticals INC. | $22.51 | 2025 | |
| Amicus Therapeutics, INC. | $18.23 | 2019 | |
| Ardelyx, INC. | $17.35 | 2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $17.03 | 2024 | Xarelto |
| Chiesi USA, INC. | $15.86 | 2025 | Elfabrio |
| Horizon Therapeutics Plc | $13.59 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.88 | 2022 | |
| Opko Pharmaceuticals, LLC | $11.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prem Chandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.